This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan in 7-10 daily inhalations 1 time per day.
It was previously shown that in ultra-low (more than 100 times lower than conventional therapeutic) doses inhalations of alkylating drug (melphalan) are effective in severe steroid-resistant bronchial asthma, a form of the disease often characterised by neutrophilic type of inflammation. The exacerbation frequency reduced after the treatment, steroid-sparing effect was shown, morphological signs of bronchial epithelial regeneration were revealed and quality of life of asthmatic patients, treated with ultra-low doses of melphalan, improved. In preclinical studies and studies with volunteers, it was found that inhalations of ultra-low doses of melphalan do not have cytotoxic properties, but have local and systemic anti-inflammatory effects and decrease the activation of lymphocytes due to blockade of heavy β-chain of the interleukin (IL)-2 surface receptor. In addition, in ultra-low concentrations, alkylating agents are able to disrupt the cell signalling through the receptor for tumor necrosis factor (TNF), thereby exerting a protective effect from the cytotoxic activity of TNF-α, which leads to the anti-inflammatory response. Taking into account, that severe cases of COVID are characterised with hyperergic inflammatory response (and in some cases even with the development of "cytokine storm") it can be assumed that the inhalation use of low-doses of melphalan due to its anti-inflammatory properties can be effective treatment for patients with COVID-associated pneumonia.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Inhalations with low doses of Melphalan for 7-10 consequent days
the patients will receive only SOC (standard of care) treatment
Kirill Zykov
Moscow, Russia
RECRUITINGClinical hospital
Moscow, Russia
RECRUITINGThe changes of COVID Ordinal Outcomes Scale
The number of patients with the clinical improvement is defined as an improvement of two points (from the status at baseline) on an ordinal scale of clinical improvement on day 28 or discharge from hospital ( whatever occurs earlier) 1. Death 2. Hospitalized with Invasive mechanical ventilation plus additional organ support - ECMO / pressors / RRT 3. Hospitalized with intubation and mechanical ventilation 4. Hospitalized on non-invasive ventilation or high flow oxygen. 5. Hospitalized on a mask or nasal prongs. 6. Hospitalized no oxygen therapy. 7. Ambulatory, with limitation of activities. 8. Ambulatory, no limitation of activities. I. No clinical or virological evidence of infection.
Time frame: baseline vs Day 14, day 28
Percentage of the patients with Clinical Recovery
Percentage of the patients with clinical recovery which is defined as a normalisation of fever, respiratory rate, and oxygen saturation, and improvement of cough, sustained for at least 72 hours, or live hospital discharge, whichever comes first. Normalization and improvement criteria: * Fever - \<37°C, * Respiratory rate - ≤24/minute on room air, * Oxygen saturation - \>94% on room air, * Cough - mild or absent on a patient reported scale of severe, moderate, mild, absent.
Time frame: baseline vs day 7, day 14, day 28
The changes of the Borg's scale
The evaluation of changes in modified Borg dyspnea scale. From 0 to 10 units.A lower score means a better clinical result (0 is the absence of dyspnea, and 10 - is maximal dyspnea). Minimal clinically important difference is 1 unit.
Time frame: Baseline vs day 7, day 14, day 28
CRP level
Change in C-reactive protein (CRP) level from baseline in mg/ml. A lower level of CRP means a better clinical result.
Time frame: baseline, day 7, Day 14, Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Lymphocyte count
Change in blood absolute lymphocyte count from baseline. A higher number of lymphocytes means a better clinical result.
Time frame: baseline, day 7, Day 14, Day 28
D-dimer
Change in blood D-dimer level from baseline. A lower level of D-dimer means a better clinical result.
Time frame: baseline, day 7, Day 14, Day 28
IL-6
Change in peripheral blood IL-6 level from baseline. A lower level of IL-6 means a better clinical result.
Time frame: baseline, day 7, Day 14, Day 28
Percentage of patients without artificial lung ventilation
Percentage of patients without artificial lung ventilation during the study. A lower percentage of patients means a better clinical result.
Time frame: baseline, day 7, Day 14, Day 28